

## CIMERLI Solutions<sup>™</sup> Part of the Coherus Solutions<sup>™</sup>

family of patient support services





Working together to ensure patient access

#### CIMERLI Solutions™ provides patient support services designed to **remove hurdles to access CIMERLI™**



#### Reimbursement support provided by **Patient Access Specialists**

- » Product-specific benefit verification
- » Coverage, coding, and reimbursement
- » Prior authorization (PA) services
- » Appeals assistance
- » Product replacement support

# Patient support through customized programs

- » The Co-Pay Savings Program
- » The Patient Assistance Program (PAP)
- » Independent Foundation Support

#### Access support provided by Field Reimbursement Managers (FRMs)

» HIPAA compliant support throughout the reimbursement process



### The CIMERLI Solutions™ **Co-Pay Savings Program**

May reduce out-of-pocket costs for eligible patients with commercial insurance\*



- » Covered costs include co-pay, coinsurance and/ or deductibles
- > \$15,000 maximum benefit/calendar year for drugs costs

#### **Injection Administration**



\$1,000 maximum benefit/ calendar year for injection administration costs

#### To enroll in the CIMERLI Solutions™ Co-Pay Savings Program please visit <u>CIMERLI.com/support</u> or call 1-844-483-3692

\*Patient Eligibility Criteria

- Be prescribed CIMERLI™ for a medically appropriate purpose consistent with its FDA-approved labeling within 180 days of program enrollment
- Have commercial (private or non-governmental) health insurance that covers the medication costs of CIMERLI™
- · Over the age of 18 years old and a US resident
- For Administration: Not a resident or get treatments in Minnesota, Rhode Island
- If a resident of Massachusetts, injection administration may only be paid directly to the patient. Additional information may be required
- Not covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or TRICARE
- Not seek reimbursement from any third-party, including payers, charitable foundations, or flexible spending account (FSAs) or healthcare savings accounts (HSAs) for all or any part of the benefit received by Coherus through this program
- Other restrictions apply, see full <u>Terms & Conditions</u> on page 7
- · It is not valid for cash paying patients or where prohibited by law
- Cimerli co-pay program subject to change or discontinuation without notice. This is not health insurance

#### Patient Assistance Program

#### CIMERLI Solutions<sup>™</sup> provides **support for eligible patients** who are unable to afford their medication.

- Patients receiving CIMERLI™ with no insurance or who are insured with traditional Medicare fee-for-service (FFS) that demonstrate financial hardship and cannot afford their cost-sharing obligation may be eligible.
- Patients with other government insurance, including Medicare Advantage, Medicare Part D, Fee-for-service Medicaid, Managed Medicaid, Veterans Affairs, Department of Defense, TRICARE, or any other insurance that is federally or state-funded are NOT eligible.
- » CIMERLI<sup>™</sup> may be provided at no cost to eligible underinsured\* patients with financial hardship through the Patient Assistance Program (PAP).
- » CIMERLI Solutions<sup>™</sup> may be able to assess patient eligibility for retrospective patient assistance. Please contact CIMERLI Solutions<sup>™</sup> at 1-844-483-3692 for additional information.
- » Medicare patients are NOT eligible for retrospective patient assistance.

To learn more about the Patient Assistance Program, <u>including full eligibility requirements</u>, please visit <u>CIMERLI.com/support</u> or call 1-844-483-3692.

#### Independent Foundation Support

# CIMERLI Solutions<sup>™</sup> may be able to help your patients find **financial support through independent foundations**

» Charitable organizations may be able to provide financial assistance if your patients have commercial insurance or governmental insurance, including Medicare and Medicaid.<sup>†</sup>


\*To be considered underinsured, the patient does not have coverage for CIMERLI™ or any other anti-VEGF or ranibizumab product.

<sup>+</sup>These organizations have their own program eligibility rules.

# Field Reimbursement Managers (FRMs) can help you streamline patient access to CIMERLI™

#### FRMs are available to provide:

- » In-depth portal education
- » Assistance in identifying and resolving reimbursement issues
- » Education to healthcare providers and staff on:
  - -Treatment approval process
  - -Patient assistance programs
  - -National and local payer policies
- » Billing and coding support
- » Appeals support



#### CIMERLI™ CO-PAY SAVINGS SUPPORT PROGRAM

#### (Combined) Drug & Injection Co-Pay Support:

Coherus' CIMERLI™ Drug Co-Pay Program may cover a portion of out-of-pocket costs associated with CIMERLI™ for eligible patients with commercial insurance. Under the program, assistance with drug co-pay costs is available up to \$15,000 per calendar year. Eligible patients could pay as little as \$0 per injection for CIMERLI™ if they meet the eligibility criteria, listed below.

Coherus' Administration Co-Pay Program may cover a portion of administration fees associated with the injection of CIMERLI™ for eligible patients with commercial insurance. Under the program, assistance with injection co-pay costs is available up to \$1,000 per calendar year. Eligible patients could pay as little as \$0 per injection for CIMERLI™ if they meet the eligibility criteria, listed below:

### Patient Drug and Administration Co-pay Eligibility Criteria:

- Be prescribed CIMERLI™ for a medically appropriate purpose consistent with its FDAapproved labeling within 180 days of program enrollment
- Have commercial (private or non-governmental) health insurance that covers the medication costs of CIMERLI™
- Over the age of 18 years old and a US resident
- For Administration: Not a resident or get treatments in Minnesota, Rhode Island
  - If a resident of Massachusetts, injection administration may only be paid directly to the patient. Additional information may be required
- Not covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or TRICARE
- Not seek reimbursement from any third-party, including payers, charitable foundations, or flexible spending account (FSAs) or healthcare savings accounts (HSAs) for all or any part of the benefit received by Coherus through this program
- Other restrictions apply, see <u>Terms & Conditions\*</u>
- Not valid for cash paying patients or where prohibited by law
- CIMERLI™ Co-Pay Program subject to change or discontinuation without notice. This is not health insurance.

#### \*Terms & Conditions

Coherus' Drug Co-Pay Program and Administration Co-Pay Program are different programs with unique eligibility for each. Patients must enroll separately as needed. To receive co-pay assistance for drug or administration co-pay costs, the provider, patient, or caregiver must enroll eligible individual within 180 days after the date of service for which the subsidy is sought.

Participating patients, pharmacies, physician offices and hospitals may use Coherus' patient services web portal or fax completed enrollment forms to 1-877-226-6370 to enroll patients. Under the CIMERLI™ Drug Co-Pay Program, if a patient incurs a co-pay obligation for the cost of CIMERLI™, and meets all eligibility requirements, Coherus shall subsidize the cost of drug up-to \$15,000 per calendar year.

Under the CIMERLI<sup>™</sup> Injection Administration Co-Pay program, if a patient incurs a co-pay obligation for the administration of CIMERLI<sup>™</sup>, and meets all eligibility requirements, Coherus shall subsidize the cost of administration up-to \$1,000 per calendar year.

The program benefits will reset every January 1st. Re-enrollment in the programs is required at regular intervals. Patients may participate in the programs as long as the patient re-enrolls as required by Coherus BioSciences and continues to meet all of the eligibility requirements for each program during participation in the programs. After reaching the maximum benefit for either program, the patient will be responsible for all remaining out-of-pocket expenses. The amount of each of the program's benefits cannot exceed the patient's out-of-pocket expenses for the cost of the drug or administration fees associated with CIMERLI<sup>TM</sup>.

The programs are not valid if the costs are eligible to be reimbursed in their entirety by private insurance plans or other programs. The programs are not valid for patients receiving assistance from any other third party, including charitable organizations, if assistance is for the same expenses covered by the programs. The administration assistance cannot be combined with any other rebate, free trial or similar offer for the medication or administration of the product unless otherwise permitted by Coherus. These programs are not health insurance or a benefit plan.


All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. The programs are only valid in the United States and US Territories and otherwise void where prohibited by law, including in Minnesota, Rhode Island. In Massachusetts, Minnesota, and Rhode Island special conditions apply. The injection administration copay may only be paid directly to the patient. Additional information may be required to facilitate payment directly to the patient. Co-Pay Program benefits may not be sold, purchased, traded or offered for sale.

The programs do not obligate use of any specific product or provider. Healthcare providers may not advertise or otherwise use the programs as a means of promoting their services or Coherus products to patients. Coherus reserves the right to rescind, revoke or amend the program without notice at any time.



Working together to ensure patient access

## CIMERLI Solutions™ provides patient support designed to **remove hurdles to access CIMERLI™**



- » Reimbursement support provided by Patient Access Specialists
- » May reduce out-of-pocket costs for eligible patients with commercial insurance
- Support for eligible patients who are unable to afford their medication
- » Help for your patients to find financial support through independent foundations
- » Field Reimbursement Managers (FRMs) can help you streamline patient access to CIMERLI™

#### Please contact us at:



(ranibizumab-eqrn) injection

Coherus reserves the right to revise or terminate the Coherus Solutions™ program without notice at any time.

CIMERLI, CIMERLI Solutions, and Coherus Solutions are trademarks of Coherus BioSciences, Inc. © 2022 Coherus BioSciences, Inc. All rights reserved. 0722-CIM-P090



Working together to ensure patient access